<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="171202">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867724</url>
  </required_header>
  <id_info>
    <org_study_id>190-CLD-AOS</org_study_id>
    <nct_id>NCT00867724</nct_id>
  </id_info>
  <brief_title>Clinical Study-evaluate Performance&amp;Safety &quot;Aer-O-Scope&quot; in Colon of Low Risk Patients</brief_title>
  <official_title>A Clinical Study to Evaluate the Performance &amp; Safety of the &quot;Aer-O-Scope&quot; Traveling Through the Colon in Low Risk Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI View Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GI View Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double center study to evaluate the safety and efficacy of the Aer-O-Scope in traveling
      through the colon in low risk subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asymptomatic adults between the ages of 18 and 70 will undergo screening of the colon using
      the aer-o-scope, under fluoroscopy, following by screening of the colon using a standard
      approved colonoscopy for determination of safety.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to screen the entire length of the colon to the cecum.</measure>
    <time_frame>30 -60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Aeroscopy/Colonoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Observational study - training cohort and study cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>aeroscopy (aer-o-scope)</intervention_name>
    <description>screening of the colon for crc using the aer-o-scope</description>
    <arm_group_label>Aeroscopy/Colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 18 and 70 years of age

          -  Patients who are generally healthy and classified as low risk for CRC

          -  Patients who are ready to undergo standard colonoscopy examination including colon
             prep.

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients with any known GI related symptoms complaints or GI diseases

          -  Patients with cancer or other life threatening diseases or conditions

          -  Patients with unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal'
             gastrointestinal, genitourinary, hematological, coagulation, immunological,
             endocrine/metabolic, or other medical disorder that, in the opinion of the
             investigator, would confound the study results or compromise patient safety. Patients
             with a known history of blood clotting problems and /or who are on anti-coagulant
             therapy and cannot stop treatment for the purpose of this study. (Patients taking up
             to 100mg aspirin for prophylactic treatment are acceptable for this study).

          -  Pregnant women

          -  Patients who underwent abdominal surgery that is deemed by the investigator to effect
             the procedure

          -  Morbid Obesity (BMI &gt; 40)

          -  Drug abuse or alcoholism

          -  Bed-ridden patient

          -  Inadequate communication with the patient

          -  Patients under custodial care

          -  Participation in current clinical study or clinical study within 30 days prior to the
             procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erwin M Santo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Santo, MD</last_name>
      <phone>972-3-697-4969</phone>
      <email>erwin@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ervin Santo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 9, 2011</lastchanged_date>
  <firstreceived_date>March 23, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Dr. Erwin Santo</name_title>
    <organization>Souraski Medical Center</organization>
  </responsible_party>
  <keyword>polyp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
